On November 18, 2024, Humacyte, Inc. announced the presentation of positive preclinical results for its small-diameter acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG). The data was presented at The American Heart Association’s Scientific Sessions 2024 meeting.
In a six-month preclinical study in primates, the sdATEV demonstrated sustained patency, recellularized with the animals’ host cells, and remodeled to effectively reduce the initial size mismatch between the sdATEV and the native artery. These findings suggest the sdATEV could be a promising off-the-shelf alternative to native vessel grafts in CABG.
The successful preclinical outcomes support Humacyte's efforts to advance this product candidate, which targets a significant unmet medical need in the treatment of coronary artery disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.